Clearpoint Neuro Stock Today
| CLPT Stock | USD 5.66 0.08 1.39% |
Performance0 of 100
| Odds Of DistressLess than 39
|
Clearpoint Neuro is selling for under 5.66 as of the 12th of June 2024; that is -1.39 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 5.62. Clearpoint Neuro has about a 39 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Clearpoint Neuro are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of March 2024 and ending today, the 12th of June 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 12th of February 2020 | Category Healthcare | Classification Health Care |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 27.42 M outstanding shares of which 1.2 M shares are currently shorted by private and institutional investors with about 9.97 trading days to cover. More on Clearpoint Neuro
Moving together with Clearpoint Stock
Moving against Clearpoint Stock
| 0.38 | ELV | Elevance Health Financial Report 17th of July 2024 | PairCorr |
| 0.33 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
Clearpoint Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Joseph Burnett | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Collplant Holdings Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clearpoint Neuro can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Clearpoint Neuro's financial leverage. It provides some insight into what part of Clearpoint Neuro's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clearpoint Neuro (CLPT) is traded on NASDAQ Exchange in USA. It is located in 120 S. Sierra Avenue, Solana Beach, CA, United States, 92075 and employs 107 people. Clearpoint Neuro is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 157.39 M. Clearpoint Neuro conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 27.42 M outstanding shares of which 1.2 M shares are currently shorted by private and institutional investors with about 9.97 trading days to cover.
Clearpoint Neuro currently holds about 45.14 M in cash with (13.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84.
Check Clearpoint Neuro Probability Of Bankruptcy
Ownership Allocation30% of Clearpoint Neuro outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check Clearpoint Ownership Details
Clearpoint Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 162 K | |
| Awm Investment Company Inc | 2024-03-31 | 131.4 K | |
| Legato Capital Management Llc | 2024-03-31 | 130.7 K | |
| Parsons Capital Management Inc | 2024-03-31 | 105.9 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 93.1 K | |
| Manatuck Hill Partners Llc | 2024-03-31 | 75 K | |
| Bridgeway Capital Management, Llc | 2024-03-31 | 67 K | |
| Charles Schwab Investment Management Inc | 2024-03-31 | 62.8 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 62 K | |
| Blackrock Inc | 2023-12-31 | 1.5 M | |
| Vanguard Group Inc | 2024-03-31 | 1.3 M |
Clearpoint Neuro Historical Income Statement
Clearpoint Stock Against Markets
Clearpoint Neuro Corporate Management
| Mazin Sabra | Chief Officer | Profile | |
| Danilo DAlessandro | Chief Officer | Profile | |
| Ellisa Cholapranee | General Secretary | Profile | |
| Jeremy Stigall | Executive Delivery | Profile | |
| Jacqueline Keller | Vice Marketing | Profile |
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.